Interview with Dr. David Yang, President, MicroConstants China
Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how that came about? It all began when…
Address: Suite 1-201, Building 18
99 Kechuang 14th Street
BDA, Beijing 101111
P.R.China
Tel: +86 (10) 59776728
Web: http://www.microconstants.com.cn/
MicroConstants China is a Contract Research Organization (CRO) that provides premier quality bioanalytical services, integrated clinical trial management services，IND-enabling drug metabolism (DMPK) assays, pharmacokinetic analysis, ELISA immunoassay, biomarker analysis, and quality system consulting to pharmaceutical/biotech companies and research institutes worldwide. Our in-house OECD GLP compliant bioanalytical laboratory specializes in method development, method validation, and sample analysis of small molecules, proteins, and peptides using LC/MS/MS, HPLC/UV, and ELISA for preclinical and clinical PK samples.
Our mission is to provide GLP/GCP compliant preclinical and clinical contract service in China to meet global product registration requirement.
Our goal is to conduct contract research service according to global recognized quality standards to ensure data integrity, accuracy, traceability and safety. Through vigorous audit of data, qualification and training of our partnering clinical site, open communication and quick resolve of our clients’ concern, we expedite our clients drug development process by providing data that meet various regulatory agencies requirement.
Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how that came about? It all began when…
Since it was established in 1988, PhIRDA, an organization that groups together China’s pharma innovators, research institutions and investors has played an active role in the evolution of China’s biopharma…
Han Yahui from Chinese folic acid specialist Scrianen outlines her company’s role in keeping mothers and newborns healthy in China, Scrianen’s approach to international partnerships, and the next horizons in…
In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China…
Prof. Song Ruilin outlines the Chinese (bio)pharmaceutical industry’s progress across the three key pillars of innovation, industrialization, and internationalization in recent years. While a downturn in the global economy and…
Chinese biotech Jacobio has made remarkable strides in pioneering first-in-class drug research, with their SHP2 inhibitor project only the second globally to initiate a clinical trial for a novel target…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer,…
The latest news from Chinese pharma, including progress on the US Senate bill targeting BGI and WuXi AppTec, a report on why drug research is slowing in the country, and…
No longer a fledgling biotech, oncology-focused BeiGene, originally created in China in 2010 with the idea of carrying out world-class research there, has since expanded its global reach and garnered…
The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics;…
Two leading regional pharma executives, from Eli Lilly and Boehringer Ingelheim respectively have recently moved to head up China operations; perhaps a sign that despite recent geopolitical tensions, multinational biopharma…
The latest pharma industry and healthcare news coming out of China including AstraZeneca’s acquisition of Gracell Biotechnologies; the alarming drop in enrolment in China’s state health insurance system; Huadong Medicine/Impact…
The APAC region —with an approximate ten percent growth in trial numbers between 2017 and 2022— is rapidly becoming the world’s leading market for clinical trials. Karen Chu, CEO of…
See our Cookie Privacy Policy Here
